免疫检查点抑制剂迟发与持久免疫相关不良事件被忽视
该研究回顾FDA/EMA批准的ICI注册试验及洛桑大学医院437例肺癌和黑色素瘤真实世界数据,发现迟发和持久irAEs报告不足但常见,约35.2%的irAEs持续≥6个月,时间依赖分析未显示irAEs与OS显著相关。
要点
- 注册试验中90%未报告irAEs持续时间及数据截止时持续毒性比例
- 真实世界中35.2%的irAEs为持久性(≥6个月),约40%在随访期间未缓解
- 时间依赖分析未发现irAEs与OS显著相关,需真实世界证据指导随访
核心结论
- 迟发和持久irAEs在ICI治疗中报告不足但常见,需真实世界证据全面捕获以制定监测随访策略。
- 推荐使用时间依赖生存分析评估irAEs对OS的影响。
研究设计与样本
- 回顾性分析FDA/EMA批准的ICI注册试验(截至2019年12月)及洛桑大学医院2011-2019年437例肺癌和黑色素瘤真实世界数据。
主要发现
- 56/62(90%)注册试验出版物未说明irAEs持续时间及数据截止时持续毒性比例。
- 437例患者中229例(52.4%)发生至少1次≥2级毒性,共318例irAEs,其中112例(35.2%)为持久性(≥6个月),约40%在中位随访369天[194-695]或患者死亡时仍持续。
- 从治疗开始irAE累积发生概率在6、12、24个月分别为42.8%、51.0%、57.3%。
- 从首次毒性发生起持续毒性比例在6、12、24个月分别为42.8%、38.4%、35.7%。
- 时间依赖分析显示irAEs发生率与OS无显著关联(肺癌log Rank p=0.67,黑色素瘤p=0.19)。
关键数值与推荐
- 持久性irAE定义为持续时间≥6个月。
- ≥2级毒性共229例(52.4%),irAEs总数318例,持久性112例(35.2%)。
临床怎么用
- 临床应关注ICI治疗中的迟发和持久irAEs,加强长期监测和随访。
- 评估irAEs对生存影响时建议采用时间依赖分析以避免永生时间偏倚。
局限性
- 真实世界数据仅来自单中心(洛桑大学医院),样本为肺癌和黑色素瘤患者。
- 注册试验分析限于截至2019年12月的FDA/EMA批准试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immune checkpoint inhibitors (ICIs) have revolutionised cancer therapy but frequently cause immune-related adverse events (irAEs). Description of late-onset and duration of irAEs in the literature is often incomplete. METHODS: To investigate reporting and incidence of late-onset and long-lasting irAEs, we reviewed all registration trials leading to ICI's approval by the US FDA and/or EMA up to December 2019. We analysed real-world data from all lung cancer (LC) and melanoma (Mel) patients treated with approved ICIs at the University Hospital of Lausanne (CHUV) from 2011 to 2019. To account for the immortal time bias, we used a time-dependent analysis to assess the potential association between irAEs and overall survival (OS). RESULTS: Duration of irAEs and proportion of patients with ongoing toxicities at data cut-off were not specified in 56/62 (90%) publications of ICIs registration trials. In our real-world analysis, including 437 patients (217 LC, 220 Mel), 229 (52.4%) experienced at least one grade ≥2 toxicity, for a total of 318 reported irAEs, of which 112 (35.2%) were long-lasting (≥6 months) and about 40% were ongoing at a median follow-up of 369 days [194-695] or patient death. The cumulative probability of irAE onset from treatment initiation was 42.8%, 51.0% and 57.3% at 6, 12 and 24 months, respectively. The rate of ongoing toxicity from the time of first toxicity onset was 42.8%, 38.4% and 35.7% at 6, 12 and 24 months. Time-dependent analysis showed no significant association between the incidence of irAEs and OS in both cohorts (log Rank p = 0.67 and 0.19 for LC and Mel, respectively). CONCLUSIONS: Late-onset and long-lasting irAEs are underreported but common events during ICIs therapy. Time-dependent survival analysis is advocated to assess their impact on OS. Real-world evidence is warranted to fully capture and characterise late-onset and long-lasting irAEs in order to implement appropriate strategies for patient surveillance and follow-up.
引用
- Ghisoni E, Wicky A, Bouchaab H, et al. Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy. Eur J Cancer. 2021. PMID: 33865201. doi:10.1016/j.ejca.2021.03.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。